Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Graph

REPL Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $49.28M; Selling, general and administrative $18.97M; Operating expenses $68.25M.
  • 2026-03-31: Revenue (m); Research and development $52.32M*; Selling, general and administrative (m); Operating expenses $73.34M*.
  • 2025-12-31: Revenue (m); Research and development $53.14M; Selling, general and administrative (m); Operating expenses $71.87M.
  • 2025-09-30: Revenue (m); Research and development $57.88M; Selling, general and administrative (m); Operating expenses $84.29M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)$49.28M$18.97M$68.25M(m)-$69.77M
2026-03-31(m)$52.32M*(m)$73.34M*-$240.00K*-$73.18M*
2025-12-31(m)$53.14M(m)$71.87M-$311.00K-$70.93M
2025-09-30(m)$57.88M(m)$84.29M$0.00-$83.10M
2025-06-30(m)$57.84M$32.58M$90.42M$0.00-$86.69M
2024-12-31(m)$48.00M(m)$66.02M$575.00K-$66.34M
2024-09-30(m)$43.45M(m)$58.92M$0.00-$53.05M
2024-06-30(m)$42.97M(m)$57.37M$0.00-$53.77M
2023-12-31(m)$42.85M(m)$56.54M$473.00K-$51.12M
2023-09-30(m)$49.10M(m)$63.83M-$201.00K-$60.04M
2023-06-30(m)$40.44M(m)$55.65M$201.00K-$49.55M
2022-12-31(m)$30.26M(m)$41.63M$0.00-$39.69M
2022-09-30(m)$28.83M(m)$41.58M$0.00-$43.10M
2022-06-30(m)$29.48M(m)$40.88M$0.00-$42.25M
2021-12-31(m)$19.35M(m)$29.70M(m)-$29.67M
2021-09-30(m)$19.90M(m)$29.25M(m)-$29.36M
2021-06-30(m)$18.55M(m)$27.38M(m)-$27.31M
2021-03-31(m)(m)(m)$22.18M(m)-$21.50M
2020-12-31(m)$14.32M(m)$20.27M(m)-$21.78M
2020-09-30(m)$14.05M(m)$19.66M(m)-$20.09M
2020-06-30(m)$12.16M(m)$17.83M(m)-$17.49M
2020-03-31(m)(m)(m)$16.39M(m)-$15.79M
2019-12-31(m)$11.95M(m)$16.66M(m)-$16.19M
2019-09-30(m)$8.17M(m)$12.24M(m)-$11.14M
2019-06-30(m)$7.46M(m)$10.91M(m)-$9.51M
2019-03-31(m)(m)(m)$7.83M(m)-$6.66M
2018-12-31(m)$7.86M(m)$10.14M(m)-$7.67M
2018-09-30(m)$4.96M(m)$7.10M(m)-$6.46M
2018-06-30$0.00$3.94M(m)$5.88M(m)-$10.04M
2018-03-31(m)(m)(m)$7.07M(m)-$7.14M
2017-12-31(m)$3.57M(m)$4.73M(m)-$4.35M
2017-09-30(m)$3.15M(m)$4.26M(m)-$4.66M
2017-06-30(m)$2.29M(m)$3.18M(m)-$3.55M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$115.72M$174.72M$0.00-$169.79M
2024-09-30(m)$86.42M$116.28M$0.00-$106.83M
2023-09-30(m)$89.54M$119.48M$0.00-$109.60M
2022-09-30(m)$58.31M$82.45M$0.00-$85.36M
2021-09-30(m)$38.46M$56.63M(m)-$56.67M
2020-09-30(m)$26.21M$37.50M(m)-$37.59M
2019-09-30(m)$15.63M$23.15M(m)-$20.65M
2018-09-30$0.00$8.90M$12.98M(m)-$16.50M
2017-09-30(m)$5.44M$7.43M(m)-$8.21M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$168.86M$246.58M-$311.00K-$240.72M
2024-12-31(m)$135.47M$182.30M$575.00K-$173.17M
2023-12-31(m)$132.38M$176.02M$473.00K-$160.72M
2022-12-31(m)$88.57M$124.08M$0.00-$125.05M
2021-12-31(m)$57.81M$86.33M(m)-$86.34M
2020-12-31(m)$40.53M$57.77M(m)-$59.37M
2019-12-31(m)$27.57M$39.81M(m)-$36.84M
2018-12-31$0.00$16.76M$23.12M(m)-$24.18M
2017-12-31(m)$9.01M$12.16M(m)-$12.85M

Revenue and expense 12 month

Period endResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-03-31$221.18M$98.73M$319.92M-$551.00K-$313.90M
2025-03-31$189.45M$72.18M$261.63M$468.00K-$247.30M
2024-03-31$174.96M(m)$234.77M$408.00K-$215.80M
2023-03-31$126.53M(m)$177.08M$288.00K-$174.28M
2022-03-31$79.55M(m)$118.31M$0.00-$118.04M
2021-03-31$56.75M(m)$79.95M$0.00-$80.87M
2020-03-31$38.76M(m)$56.20M$0.00-$52.63M
2019-03-31$22.17M(m)$30.95M$0.00-$30.83M
2018-03-31$13.52M(m)$19.23M$0.00-$19.70M
2017-03-31$6.94M(m)$9.65M$0.00-$7.70M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B